SG11201804801SA - Antibody molecules which bind tnf alpha - Google Patents

Antibody molecules which bind tnf alpha

Info

Publication number
SG11201804801SA
SG11201804801SA SG11201804801SA SG11201804801SA SG11201804801SA SG 11201804801S A SG11201804801S A SG 11201804801SA SG 11201804801S A SG11201804801S A SG 11201804801SA SG 11201804801S A SG11201804801S A SG 11201804801SA SG 11201804801S A SG11201804801S A SG 11201804801SA
Authority
SG
Singapore
Prior art keywords
ucb
international
ipd
berkshire
slough
Prior art date
Application number
SG11201804801SA
Inventor
Ralph Adams
Pallavi Bhatta
Emma Dave
Sam Philip Heywood
David Paul Humphreys
Diane Marshall
Daniel John Lightwood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201804801SA publication Critical patent/SG11201804801SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id .... .....1 (43) International Publication Date r ,„„0 22 June 2017(22.06.2017) WIPO I PCT ID Hit (10) WO International 2017/102833 1111111111111111111111111111111111111111111111111111t111111111IIIIII Publication Al Number (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/24 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 14/525 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2016/080984 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 14 December 2016 (14.12.2016) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 1522394.4 18 December 2015 (18.12.2015) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Allee de la Recherche, 1070 Brussels (BE). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: ADAMS, Ralph; c/o IPD, UCB Celltech, 208 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Bath Road, Slough Berkshire SL1 3WE (GB). BHATTA, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Pallavi; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DAVE, Emma; c/o IPD, UCB SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Celltech, 208 Bath Road, Slough Berkshire SL1 3WE GW, KM, ML, MR, NE, SN, TD, TG). (GB). HEYWOOD, Sam Philip; c/o IPD, UCB Celltech, Declarations under Rule 4.17: 208 Bath Road, Slough Berkshire SL1 3WE (GB). be — granted a HUMPHREYS, David Paul; IPD, UCB Celltech, 208 as to applicant's entitlement to apply for and c/o patent (Rule 4.170) Bath Road, Slough Berkshire SL1 3WE (GB). MAR- SHALL, Diane; c/o IPD, UCB Celltech, 208 Bath Road, — of inventorship (Rule 4.17(iv)) Slough Berkshire SL1 3WE (GB). Published: (74) Agent: BLANCHARD, Amanda; UCB INTELLECTUAL with international search report (Art 21(3)) PROPERTY, c/o UCB Celltech, 208 Bath Road, Slough — with sequence listing of description (Rule 5.2(a)) Berkshire SL1 3WE (GB). part Il .4t M M Ge ei O 1-1 it-- 1-1 O ei (54) Title: ANTIBODY MOLECULES WHICH BIND TNF ALPHA 52 (57) : The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody mo - .,- lecules and methods for producing said antibody molecules.
SG11201804801SA 2015-12-18 2016-12-14 Antibody molecules which bind tnf alpha SG11201804801SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522394.4A GB201522394D0 (en) 2015-12-18 2015-12-18 Antibodies
PCT/EP2016/080984 WO2017102833A1 (en) 2015-12-18 2016-12-14 Antibody molecules which bind tnf alpha

Publications (1)

Publication Number Publication Date
SG11201804801SA true SG11201804801SA (en) 2018-07-30

Family

ID=55311230

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804801SA SG11201804801SA (en) 2015-12-18 2016-12-14 Antibody molecules which bind tnf alpha

Country Status (18)

Country Link
US (1) US11091542B2 (en)
EP (1) EP3390446A1 (en)
JP (1) JP7082053B2 (en)
KR (1) KR20180089521A (en)
CN (1) CN108368168B (en)
AR (1) AR107071A1 (en)
AU (1) AU2016374375A1 (en)
BR (1) BR112018011862A2 (en)
CA (1) CA3007580A1 (en)
CL (1) CL2018001661A1 (en)
CO (1) CO2018006555A2 (en)
EA (1) EA036904B1 (en)
GB (1) GB201522394D0 (en)
IL (1) IL259883A (en)
MX (1) MX2018007221A (en)
RU (1) RU2018126315A (en)
SG (1) SG11201804801SA (en)
WO (1) WO2017102833A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144431B (en) * 2019-08-08 2023-04-14 神州细胞工程有限公司 Humanized anti-TNF alpha antibodies and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (en) 1987-07-01 1987-07-01 Novo Industri As immobilization
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (en) 1989-01-24 1990-07-31 EXPRESSION VECTOR SYSTEM FOR THE PRODUCTION OF QUIMERIC MONOCLONAL ANTIBODIES
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (en) 1994-02-28 1996-05-03 Procedes Machines Speciales Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
AU2365795A (en) 1995-04-20 1996-11-07 Centocor Inc. Multiple administrations of anti-tnf antibody
BRPI9707379C8 (en) * 1996-02-09 2017-12-12 Abbott Biotech Ltd pharmaceutical compositions comprising genetically engineered recombinant human antibody, and genetically engineered recombinant human antibody.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003083061A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
PT1570267E (en) 2002-12-03 2012-01-03 Ucb Pharma Sa Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
TWI439284B (en) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
DK1888640T3 (en) * 2005-05-18 2012-06-18 Ablynx Nv Enhanced nanobodies against tumor necrosis factor-alpha
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
MX2009012493A (en) 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Novel rabbit antibody humanization methods and humanized rabbit antibodies.
TW201531484A (en) * 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc Antibodies to TNF alpha and use thereof
EP2535351A3 (en) 2007-09-26 2013-04-03 UCB Pharma S.A. Dual specificity antibody fusions
JP6100463B2 (en) 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー Stable and soluble antibody that inhibits TNFα
JP6063122B2 (en) 2008-09-26 2017-01-18 ユセベ ファルマ ソシエテ アノニム Biological products
AU2009308763B2 (en) * 2008-10-31 2017-03-09 Janssen Biotech, Inc. Toll-like receptor 3 antagonists
JP5795759B2 (en) 2009-04-16 2015-10-14 アッヴィ・バイオセラピューティクス・インコーポレイテッド Anti-TNF-α antibody and use thereof
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
CL2010000019A1 (en) 2010-01-11 2010-06-11 Univ Chile Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN108314733A (en) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 The single domain antigen binding molecules of modification and its application
AR083495A1 (en) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit STABLE AND SOLUBLE ANTIBODIES
CA2816803A1 (en) 2010-11-02 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AR084210A1 (en) 2010-12-08 2013-05-02 Abbott Lab PROTEINS OF UNION TO TNF-a
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2753865A2 (en) 2011-09-06 2014-07-16 Koninklijke Philips N.V. Wire-based lighting module with 3d topography
SG11201401796SA (en) 2011-10-24 2014-10-30 Abbvie Inc Bispecific immunobinders directed against tnf and il-17
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
RU2015143833A (en) 2013-03-15 2017-04-21 Эббви Инк. BINDING PROTEINS WITH DOUBLE SPECIFICITY DIRECTED AGAINST TNFα
BR112016022055A2 (en) 2014-03-26 2017-10-24 Cell Medica Switzerland Ag alpha tnf binding elements
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3189153B1 (en) 2014-09-03 2021-06-16 Boehringer Ingelheim International GmbH Compound targeting il-23a and tnf-alpha and uses thereof
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
NO2768984T3 (en) 2015-11-12 2018-06-09
CR20180365A (en) 2015-12-16 2018-09-28 Amgen Inc PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules

Also Published As

Publication number Publication date
CN108368168B (en) 2022-03-01
EA201891445A1 (en) 2018-11-30
AR107071A1 (en) 2018-03-14
AU2016374375A1 (en) 2018-06-28
CO2018006555A2 (en) 2018-07-10
WO2017102833A1 (en) 2017-06-22
AU2016374375A8 (en) 2018-07-05
US20200291104A1 (en) 2020-09-17
BR112018011862A2 (en) 2018-12-04
CN108368168A (en) 2018-08-03
KR20180089521A (en) 2018-08-08
CL2018001661A1 (en) 2018-10-19
EP3390446A1 (en) 2018-10-24
EA036904B1 (en) 2021-01-13
JP2019508367A (en) 2019-03-28
JP7082053B2 (en) 2022-06-07
RU2018126315A3 (en) 2020-04-30
RU2018126315A (en) 2020-01-20
GB201522394D0 (en) 2016-02-03
MX2018007221A (en) 2018-08-01
CA3007580A1 (en) 2017-06-22
US11091542B2 (en) 2021-08-17
IL259883A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
SG11201804803WA (en) Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804127SA (en) Ctla4 binders
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201909656YA (en) Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
SG11201900501RA (en) Cannabis composition
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201806852PA (en) Protein purification
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201804704PA (en) Compositions and methods for decreasing tau expression